Could a simple shot replace IV therapy for tough lymphomas?
NCT ID NCT06504394
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing an injectable form of the immunotherapy drug pembrolizumab (combined with hyaluronidase to help absorption) in 66 adults with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma that has returned or not responded to prior treatment. The study aims to see how well the drug works (tumor shrinkage) and how it behaves in the body when given as a shot under the skin. It is not a cure, but a potential way to control the disease with a more convenient injection instead of an IV infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab with hyaluronidase (MK-3475A)
What this could lead to
If successful, this could offer a more convenient, injectable version of an existing immunotherapy for people with certain lymphomas that have come back or not responded to treatment.
What could go wrong
This is a phase 2 study with only 66 participants, so results are preliminary. The drug may not work as well as the intravenous version, and side effects from immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 0801)
Ankara, 06100, Turkey (Türkiye)
-
Auckland City Hospital ( Site 1001)
Auckland, 1023, New Zealand
-
Biocenter ( Site 0203)
Concepción, Biobio, 4070196, Chile
-
Bradfordhill-Clinical Area ( Site 0202)
Santiago, Region M. de Santiago, 8420383, Chile
-
Centro de Investigacion Clinica de Oaxaca ( Site 0405)
Oaxaca City, 68020, Mexico
-
Churchill Hospital ( Site 0604)
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Clinical Research Alliance ( Site 0101)
Westbury, New York, 11590, United States
-
Clínica Inmunocel ( Site 0201)
Santiago, Region M. de Santiago, 7580206, Chile
-
Comprehensive Cancer Centers of Nevada ( Site 0114)
Las Vegas, Nevada, 89169, United States
-
FALP ( Site 0207)
Santiago, Region M. de Santiago, 7500921, Chile
-
Glan Clwyd Hospital ( Site 0602)
Bodelwyddan, Denbighshire, LL18 5UJ, United Kingdom
-
Hacettepe Universite Hastaneleri ( Site 0802)
Ankara, 06230, Turkey (Türkiye)
-
Health Pharma Professional Research S.A. de C.V: ( Site 0403)
Mexico City, Mexico City, 03100, Mexico
-
Hospital Universitario 12 de Octubre-Hemathology and hemotherapy ( Site 0701)
Madrid, 28041, Spain
-
Hospital Universitario de Salamanca ( Site 0702)
Salamanca, Castille and León, 37007, Spain
-
IC La Serena Research ( Site 0204)
La Serena, Coquimbo Region, 1720430, Chile
-
Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 0703)
L'Hospitalet Del Llobregat, Barcelona, 08908, Spain
-
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0504)
Gliwice, Silesian Voivodeship, 44-102, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 0501)
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Ondokuz Mayıs Universitesi ( Site 0803)
Samsun, 55270, Turkey (Türkiye)
-
Pratia MCM Krakow ( Site 0503)
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Seoul National University Hospital-Oncology ( Site 1101)
Seoul, 03080, South Korea
-
The Christie NHS Foundation Trust ( Site 0603)
Manchester, m20 4bx, United Kingdom
-
Universitaetsklinikum Essen ( Site 1302)
Essen, North Rhine-Westphalia, 45147, Germany
-
University College London Hospital ( Site 0605)
London, London, City of, NW1 2PG, United Kingdom
-
University of Iowa - Waukee ( Site 0111)
Waukee, Iowa, 50263, United States
-
University of Iowa-Holden Comprehensive Cancer Center ( Site 0115)
Iowa City, Iowa, 52242, United States
-
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0502)
Gdansk, Pomeranian Voivodeship, 80-214, Poland
-
Westmead Hospital ( Site 0901)
Westmead, New South Wales, 2145, Australia